186 related articles for article (PubMed ID: 21787767)
1. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome.
Luo L; Zeng J; Liang B; Zhao Z; Sun L; Cao D; Yang J; Shen K
Exp Mol Pathol; 2011 Oct; 91(2):596-602. PubMed ID: 21787767
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral heterogeneity in the self-renewal and tumorigenic differentiation of ovarian cancer.
Abelson S; Shamai Y; Berger L; Shouval R; Skorecki K; Tzukerman M
Stem Cells; 2012 Mar; 30(3):415-24. PubMed ID: 22267284
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
6. Establishment of human ovarian serous carcinomas cell lines in serum free media.
Pan Z; Hooley J; Smith DH; Young P; Roberts PE; Mather JP
Methods; 2012 Mar; 56(3):432-9. PubMed ID: 22445873
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
8. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas.
Alama A; Barbieri F; Favre A; Cagnoli M; Noviello E; Pedullà F; Viale M; Foglia G; Ragni N
Gynecol Oncol; 1996 Jul; 62(1):82-8. PubMed ID: 8690298
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
11. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
13. Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery.
Tanaka T; Toujima S; Utsunomiya T; Yukawa K; Umesaki N
Oncol Rep; 2008 Jul; 20(1):13-23. PubMed ID: 18575713
[TBL] [Abstract][Full Text] [Related]
14. Characterization of primary ovarian cancer cells in different culture systems.
Liu T; Cheng W; Lai D; Huang Y; Guo L
Oncol Rep; 2010 May; 23(5):1277-84. PubMed ID: 20372841
[TBL] [Abstract][Full Text] [Related]
15. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
[TBL] [Abstract][Full Text] [Related]
16. Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations.
Katz E; Skorecki K; Tzukerman M
Clin Cancer Res; 2009 Jan; 15(1):70-80. PubMed ID: 19118034
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer stem cells.
Zeimet AG; Reimer D; Sopper S; Boesch M; Martowicz A; Roessler J; Wiedemair AM; Rumpold H; Untergasser G; Concin N; Hofstetter G; Muller-Holzner E; Fiegl H; Marth C; Wolf D; Pesta M; Hatina J
Neoplasma; 2012; 59(6):747-55. PubMed ID: 22862176
[TBL] [Abstract][Full Text] [Related]
19. PDCD4 inhibits the malignant phenotype of ovarian cancer cells.
Wei ZT; Zhang X; Wang XY; Gao F; Zhou CJ; Zhu FL; Wang Q; Gao Q; Ma CH; Sun WS; Fu QZ; Chen YH; Zhang LN
Cancer Sci; 2009 Aug; 100(8):1408-13. PubMed ID: 19493270
[TBL] [Abstract][Full Text] [Related]
20. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
